Iqra Ahmed

Qualifications

M.Phil. (Biotechnology), IBMS, Dow University of Health Sciences

Research

• •Ali S, Shalim E, Farhan F, Anjum F, Ali A, Uddin SM, Shahab F, Haider M, Ahmed I, Ali MR, Khan S. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial. Trials. 2022 Nov 8; 23(1):932.

• •Ali S, Uddin SM, Shalim E, Sayeed MA, Anjum F, Saleem F, Muhaymin SM, Ali A, Ali MR, Ahmed I, Mushtaq T. Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial. EClinical Medicine. 2021 Jun 1; 36:100926.

• •Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E, Khan M, Ahmed I, M Muhaymin S, Bukhari U, Luxmi S. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021 Apr; 13(5):397-407.

• •Ali S, Luxmi S, Anjum F, Muhaymin SM, Uddin SM, Ali A, Ali MR, Tauheed S, Khan M, Bajwa M, Baig SU, Shalim E, Ahmed I, Khan AS, Quraishy S. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Dec; 21:1-3.

• •Khan M, Ahmed I, Farooq S, Khan S, Amin R, Ali S. Probiotic potential of Saccharomyces strains isolated from Litchi chinensis (Lychee fruit). Pakistan Journal of Pharmaceutical Sciences. 2020 Jul 1; 33:1855-61.

• •Ali S, Farooq S, Naeem N, Ali A, Ahmed I, Khan M, Khan H, Baqai N, Ishrat U. Finding the root cause of frequently prevalent disease in sugarcane from some diseased fields of Sindh, Pakistan. FUUAST Journal of Biology. 2018 Dec 18; 8(2):243-7.

• •Subhan SA, Wahab A, Mujahid TY, Abbas T, Mehmood N, Ahmed I. Bioactive Metabolites from Indigenous Actinomycetes Isolated from Marine Water. Journal of Pharmacy and Nutrition Sciences. 2015; 5:57-63.